News

Enzyre is now preparing to raise an investment round. The proceeds will be used to (a) finalize the development of the ENZYPAD en ENZYCARD Hemophilia A, (b) manufacture the portable instrument & disposable, and (c) perform studies to obtain regulatory approval in EU & US. The product will be commercialized worldwide with support of our pharma partner. Interested candidate investors are encouraged to contact us at investors@enzyre.com.

Get involved

NTC interview with CEO: Enzyre uses investments to save thousands on healthcare

Enzyre closes Series A financing round of EUR 12M to advance pioneering diagnostic technology platform for hemophilia patients

Enzyre awarded REACT grant for pilot production line

Enzyre announces strategic partnership with Takeda to accelerate development of pioneering diagnostic technology platform for hemophilia patients

Enzyre wins Best Blood Coagulation Analysis Product 2020 award!

Novalis invests in Enzyre to support development of Enzypad, a breakthrough hand-held diagnostic and monitoring device

Takeda and Enzyre to develop diagnostic device allowing hemophilia patients to determine their coagulation status at home

Enzyre appoints Dirk Pollet as Chief Executive Officer

Opening new Enzyre labs at Noviotech Campus

Anneke Sijbers wins award for Enzyre

Enzyre on local television

Join us on our journey

Get in touch

Where to find us

Work with us

Follow us